Hydroxyzine Injectable Solution (Im) Suppliers & Bulk Manufacturers
Available Forms: Injectable solution (IM)
Available Strengths: 25 mg/mL, 50 mg/mL
Reference Brands: US: Vistaril®, , Atarax®; EU: Atarax®, Hydroxyzine Mylan®, Ucerax®
Category:
Antipsychotropic Drugs
Hydroxyzine acts as a first-generation antihistamine by blocking H1 receptors, reducing allergy symptoms and anxiety. It also exhibits sedative and anxiolytic properties by depressing activity in key subcortical areas of the central nervous system. It’s used for preoperative sedation, anxiety relief, and allergic reactions via intramuscular injection
Hydroxyzine Injectable solution (IM) is available in Injectable solution (IM)
and strengths such as 25 mg/mL, 50 mg/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Hydroxyzine Injectable solution (IM) is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Hydroxyzine Injectable solution (IM) can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Hydroxyzine Injectable Solution (IM) is FDA-approved in the USA for short-term use in anxiety, preoperative sedation, and allergic conditions. Its use is limited to intramuscular administration only, as intravenous or subcutaneous routes are contraindicated due to tissue irritation risks. In the European Union, its availability varies by country, often regulated under national authorization procedures, with labeling focused on CNS depression, QT prolongation, and age-specific dosing precautions. Pharmacovigilance measures, including Risk Management Plans (RMPs), are enforced. Hydroxyzine IM is valued for its rapid onset in acute care. Explore more forms at Pharmatradz.com.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing